AIDS-Related Opportunistic Infections/complications; Acquired Immunodeficiency Syndrome/complications; Anti-HIV Agents/adverse effects; Immune Reconstitution Inflammatory Syndrome/complications; Meningitis, Cryptococcal/complications; AIDS-Related Opportunistic Infections/blood; AIDS-Related Opportunistic Infections/drug therapy; AIDS-Related Opportunistic Infections/microbiology; Acquired Immunodeficiency Syndrome/blood; Acquired Immunodeficiency Syndrome/drug therapy; Acquired Immunodeficiency Syndrome/microbiology; Amphotericin B/therapeutic use; Anti-HIV Agents/therapeutic use; Antifungal Agents/therapeutic use; Antigens, Fungal/blood; Antiretroviral Therapy, Highly Active; Clinical Trials, Phase II as Topic; Fluconazole/therapeutic use; Humans; Immune Reconstitution Inflammatory Syndrome/blood; Immune Reconstitution Inflammatory Syndrome/drug therapy; Immune Reconstitution Inflammatory Syndrome/epidemiology; Immunocompromised Host; Incidence; Kaplan-Meier Estimate; Logistic Models; Meningitis, Cryptococcal/blood; Meningitis, Cryptococcal/drug therapy; Meningitis, Cryptococcal/epidemiology; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Time Factors